Entries by tomo360

ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study

About the Phase 2 CLARITY Study The study was conducted in collaboration with the MGH Clinical Trials Network & Institute (CTNI) and randomized 207 adult patients with a confirmed inadequate response to existing first-line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) therapy for MDD across 27 U.S. clinical research centers.